Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
| Conditions: | Neoplasms |
| Start Date: | November 1, 2000 |
| Phase: | Phase I |
| Status: | Terminated |
| NCT ID: | NCT00024687 |
| Study Type: | Interventional |
| Intervention: | Drug: SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Neopharm |
| Ages: | Adult|Senior |
| Enrollment: | 30 |
| Funded By: | Industry |
| First Received: | September 24, 2001 |
| End Date: | |
| Last Updated: | June 23, 2005 |
| Last Verified: | July 1, 2003 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
